Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.
Department of Biotechnology, Jamia Millia Islamia (A Central University), New Delhi, India.
J Neuromuscul Dis. 2021;8(1):125-136. doi: 10.3233/JND-200547.
Limb girdle muscular dystrophy recessive type 1 (LGMDR1, Previously LGMD2A) is characterized by inactivating mutations in CAPN3. Despite the significant burden of muscular dystrophy in India, and particularly of LGMDR1, its genetic characterization and possible phenotypic manifestations are yet unidentified.
We performed bidirectional CAPN3 sequencing in 95 LGMDR1 patient samples characterized by calpain-3 protein analysis, and these findings were correlated with clinical, biochemical and histopathological features.
We identified 84 (88.4%) cases of LGMDR1 harboring 103 CAPN3 mutations (71 novel and 32 known). At least two mutant alleles were identified in 79 (94.2%) of patients. Notably, 76% exonic variations were enriched in nine CAPN3 exons and overall, 41 variations (40%) correspond to only eight exonic and intronic mutations. Patients with two nonsense/out of frame/splice-site mutations showed significant loss of calpain-3 protein as compared to those with two missense/inframe mutations (P = 0.04). We observed a slow progression of disease and less severity in our patients compared to European population. Rarely, presenting clinical features were atypical, and mimicked other muscle diseases like FSHMD, distal myopathy and metabolic myopathies.
This is first systematic study to characterize the genetic framework of LGMDR1 in the Indian population. Preliminary calpain-3 immunoblot screening serves well to direct genetic testing. Our findings prioritized nine CAPN3 exons for LGMDR1 diagnosis in our population; therefore, a targeted-sequencing panel of nine exons could serve well for genetic diagnosis, carrier testing, counseling and clinical trial feasibility study in LGMDR1 patients in India.
肢带型肌营养不良症 1 型(LGMDR1,以前称为 LGMD2A)的特征是 CAPN3 失活突变。尽管印度的肌肉营养不良症负担巨大,尤其是 LGMDR1,但它的遗传特征和可能的表型表现尚未确定。
我们对 95 例经钙蛋白酶-3 蛋白分析特征明确的 LGMDR1 患者样本进行了 CAPN3 双向测序,并将这些发现与临床、生化和组织病理学特征相关联。
我们发现 84 例(88.4%)LGMDR1 患者携带 103 种 CAPN3 突变(71 种新突变和 32 种已知突变)。79 例(94.2%)患者至少有两种突变等位基因。值得注意的是,9 个 CAPN3 外显子中富集了 76%的外显子变异,总体上,41 个变异(40%)仅对应于 8 个外显子和内含子突变。与具有两种错义/框架内/剪接位点突变的患者相比,具有两种无义/框外/剪接位点突变的患者钙蛋白酶-3 蛋白显著缺失(P=0.04)。与欧洲人群相比,我们的患者疾病进展缓慢,病情较轻。罕见的是,临床表现不典型,类似于其他肌肉疾病,如 FSHMD、远端肌病和代谢性肌病。
这是首次在印度人群中对 LGMDR1 的遗传结构进行系统研究。初步的钙蛋白酶-3 免疫印迹筛选很好地指导了基因检测。我们的发现确定了九个 CAPN3 外显子在我们人群中用于 LGMDR1 诊断的优先级;因此,九个外显子的靶向测序panel 可很好地用于印度 LGMDR1 患者的遗传诊断、携带者检测、咨询和临床试验可行性研究。